• Español
Logotipo BioKeralty
  • Home
  • BioKeralty
  • Contact
/ Key role of BioKeralty in the NoCanTher project which tests the implementation of magnetic nanoparticles in the treatment of pancreatic cancer

Key role of BioKeralty in the NoCanTher project which tests the implementation of magnetic nanoparticles in the treatment of pancreatic cancer

Feb 25 2021
adminbk 0 Comments

In the absence
of useful therapies for any type of patients, the
NoCanTher project seeks to demonstrate the
applicability of nanoparticles in the treatment of pancreatic cancer
. Having
BioKeralty as sponsor, the clinical study was the last stage of the
European NoCanTher project, an initiative started in 2016 and funded by the
European Union’s
Horizon 2020
research and innovation program. To this aim, the clinical study has been
based on the results obtained in the preclinical stage where BioKeralty played
a key role
. BioKeralty’s research was focused on the development of
magnetic iron nanoparticles able to produce magnetic hyperthermia
so that
the heat created by these nanoparticles could be applied to sensitize cancer
cells to the standard care, or even, destroy them.

 

Hyperthermia transforms
electromagnetic energy into heat, which, combined with standard chemotherapy, destroys
tumor cells while controlling the growth of the local tumor. Despite being a
relatively new field of research, this approach may be a feasible option for
cancer patients (especially those who do not respond to the standard treatment
and in whom radiation therapy is particularly invasive). In this context,
BioKeralty has tested this new approach in patients with locally advanced
pancreatic cancer, analyzing the potential of magnetic nanoparticles to
destroy tumor cells in those people with locally advanced pancreatic cancer
.
Consequently, nanomedicine could become an alternative therapy to palliative
chemotherapy in the treatment of locally advanced, unresectable and
non-metastasized pancreatic cancer.

 

Under the
coordination of Instituto Madrileño de Estudios
Avanzados (IMDEA) – Nanonciencia, currently BioKeralty continues working
together with other ten national and international research centers in the implementation
of
nanomedicine in early clinical phases of multimodal cancer
therapy.

BioKeralty, one of the European Smart4Fabry project round-table participants

Prev Post

Patents and publications

Next Post
Leave Your Reply
Cancel reply

Your email address will not be published. Required fields are marked *

Recent posts
BioKeralty develops predictive software for diabetes and cognitive impairment
by adminbk 07/30/2021
Completion of OSASUKAT, a blockchain platform project with a system designed by BioKeralty
by adminbk 07/26/2021
Patents and publications
by adminbk 03/08/2021
Key role of BioKeralty in the NoCanTher project which tests the implementation of magnetic nanoparticles in the treatment of pancreatic cancer
by adminbk 02/25/2021
BioKeralty, one of the European Smart4Fabry project round-table participants
by adminbk 01/11/2021

Awesome Image

  • C/Albert Einstein 25, Edificio E-3, 1ª planta Oficina 2

    Parque Tecnológico de Álava,

    01510 Miñano, Vitoria-Gasteiz (Álava), España

  • BioKeralty
  • Legal
  • Privacy policy
  • Cookies policy
  • Contact

Copyright © BioKeralty 2021

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

BIOKERALTY
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.